ArticleHaematologica2024
Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis.
Abstract readLetter
In one paragraph
Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Real-world use of emapalumab in hemophagocytic lymphohistiocytosis: a scoping review of published evidence.Frontiers in pharmacology · 2026Pooled it
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Interferon-JAK-STAT Axis in Bone Metabolism.Current osteoporosis reports · 2026Review
- Chronic granulomatous disease with suspected secondary hemophagocytic lymphohistiocytosis: a case report and hypothesis-generating rationale for neuroimmune modulation.Critical care (London, England) · 2026Review
- Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study.Blood advances · 2026Article
- CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis.Blood · 2026Article
- IFN-γ Driven Hepatic Injury Exacerbates Mortality in NK/T-Cell Lymphoma-Associated Hemophagocytic Lymphohistiocytosis.Cancer medicine · 2026Article
- Neurological Involvement in Adult-Onset Secondary Hemophagocytic Lymphohistiocytosis: Clinical Features and Prognostic Implications.Brain and behavior · 2026Article
- Long-Term Treatment With Emapalumab in an Adult Patient With Refractory Hemophagocytic Lymphohistiocytosis and Systemic Lupus Erythematosus: A Case Report.Case reports in hematology · 2026Article
- Lymphoma-Associated Bone Marrow Hemophagocytosis (LA-BMHPC): A Retrospective, Single-Center Study of 67 Patients.International journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
William T JohnsonDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY. Johnsow3@mskcc.org.
Zachary D Epstein-PetersonDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.
Nivetha GanesanDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Timothy PakDepartment of Medicine, New York Presbyterian Brooklyn Methodist Hospital-Weill Cornell Medical College, New York, NY.
Tiffany ChangDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Phuong DaoDepartment of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY.
Alison J MoskowitzDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.
Robert N StuverDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.
Paola GhioneDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.
Natasha GalassoDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Niloufer KhanDepartment of Hematology and Hematopoietic Cell Transplant, Lymphoma Division, City of Hope Comprehensive Cancer, Duarte, CA.
M Lia PalombaDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.
Philip C CaronDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.
Anita KumarDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.
Roni TamariDepartment of Medicine, Weill Cornell Medical College, Cornell University, New York, NY, USA; Department of Medicine, Adult Bone Marrow Transplant and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Jennifer K LueDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.
Ariela NoyDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.
Lorenzo FalchiDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.
Andrew M IntlekoferDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Boglarka GyurkoczaDepartment of Medicine, Weill Cornell Medical College, Cornell University, New York, NY, USA; Department of Medicine, Adult Bone Marrow Transplant and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Miguel-Angel PeralesDepartment of Medicine, Weill Cornell Medical College, Cornell University, New York, NY, USA; Department of Medicine, Adult Bone Marrow Transplant and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.
Michael ScordoDepartment of Medicine, Weill Cornell Medical College, Cornell University, New York, NY, USA; Department of Medicine, Adult Bone Marrow Transplant and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY.
A Zara HerskovitsDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Gilles SallesDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.
Santosha A VardhanaDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Steven M HorwitzDepartment of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, Cornell University, New York, NY.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, MonoclonalLymphohistiocytosis, HemophagocyticSalvage TherapyAdultAgedAntibodies, NeutralizingFemaleHumansMaleMiddle AgedNeoplasmsTreatment OutcomeAntibodies, MonoclonalAntibodies, NeutralizingEmapalumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.